Innovative cancer treatments advance as Anocca raises $46 million to initiate early clinical trials of T cell receptor therapy targeting KRAS mutant pancreatic cancer. Additionally, immune checkpoint inhibitors exhibit promise in cancers of unknown primary origin, potentially improving outcomes in diagnostically challenging cases. These developments signal progress toward personalized and targeted oncology therapeutics.